lanoracopan   Click here for help

GtoPdb Ligand ID: 14660

Synonyms: Example 5 target compound [WO2022028507] | MY 008211A | MY-008 | Yishining® (China)
Approved drug Immunopharmacology Ligand
lanoracopan is an approved drug
Compound class: Synthetic organic
Comment: Lanoracopan (MY-008, MY 008211A) is an orally bioavailable small molecule inhibitor of complement factor B (CFB) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 71.03
Molecular weight 448.55
XLogP 2.53
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC(=C(CN2CC[C@@H](C[C@H]2C3=CC=C(C=C3)C(=O)O)OCC4CC4)C5=C1NC=C5)OC
Isomeric SMILES CC1=CC(=C(C2=C1NC=C2)CN3CC[C@@H](C[C@H]3C4=CC=C(C=C4)C(=O)O)OCC5CC5)OC
InChI InChI=1S/C27H32N2O4/c1-17-13-25(32-2)23(22-9-11-28-26(17)22)15-29-12-10-21(33-16-18-3-4-18)14-24(29)19-5-7-20(8-6-19)27(30)31/h5-9,11,13,18,21,24,28H,3-4,10,12,14-16H2,1-2H3,(H,30,31)/t21-,24-/m0/s1
InChI Key YJJUEZFALZMWAP-URXFXBBRSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
lanoracopan (MY008211A) was progressed as a clinical candidate for the treatment of he inflammatory conditions IgA nephropathy (IgAN) and , paroxysmal nocturnal hemoglobinuria (PNH). First approval was granted by China's NMPA in June 2026, to treat PNH.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06687174 Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) Phase 2 Interventional Wuhan Createrna Science and Technology Co., Ltd
NCT06932471 Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment Phase 3 Interventional Wuhan Createrna Science and Technology Co., Ltd
NCT06933914 Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria Phase 2/Phase 3 Interventional Wuhan Createrna Science and Technology Co., Ltd